In glioblastoma (GBM), promoter methylation of the DNA repair gene O-methylguanine-DNA methyltransferase (MGMT) is associated with beneficial chemotherapy.To analyze radiomics features for utilizing the full potential of medical imaging as biomarkers of MGMT promoter methylation.Retrospective.In all, 98 GBM patients with known MGMT (48 methylated and 50 unmethylated tumors).3.0T magnetic resonance (MR) images, containing TA region of interest (ROI) of the tumor was delineated. A total of 1665 radiomics features were extracted and quantized, and were reduced using least absolute shrinkage and selection operator (LASSO) regularization.After the support vector machine construction, accuracy, sensitivity, and specificity were computed for different sequences. An independent validation cohort containing 20 GBM patients was utilized to further evaluate the radiomics model performance.Radiomics features of TOur results provide further evidence that radiomics MR features could predict MGMT methylation status in preoperative GBM. Multiple imaging modalities together can yield putative noninvasive biomarkers for the identification of MGMT.4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1380-1387.
